Geneva, 08 June 2018 — Unitaid and Indian drug manufacturer Cipla Ltd. struck a landmark agreement today that will lower the price of the first combination therapy (containing co-trimoxazole, isoniazid and vitamin B6) that prevents opportunistic infections in people living with HIV.

Cipla launches Q-TIB globally, a novel fixed dose combination in a single tablet for TB prophylaxis in HIV.